Literature DB >> 26253181

A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description.

Roman Shrestha1, Archana Krishnan2, Frederick L Altice3, Michael Copenhaver4.   

Abstract

BACKGROUND: Real-world clinical settings like addiction treatment programs are ill-equipped to deploy and sustain the existing resource-demanding evidence-based interventions (EBIs) that target HIV-infected people who use drugs (PWUDs), and this has left a critical void in current HIV prevention efforts. In response to this unmet need, we have conducted formative research in addiction treatment settings that has resulted in Holistic Health for HIV (3H+) - an empirically adapted, substantially abbreviated version of Holistic Health Recovery Program (HHRP+), a CDC-recommended EBI targeting HIV-infected PWUDs.
METHODS: Using a non-inferiority randomized controlled trial design, we will determine whether the abbreviated 3H+ intervention is comparable (i.e., within a 10% margin) and cost-effective relative to the original HHRP+ intervention in terms of reducing HIV risk behaviors and improving antiretroviral therapy (ART) adherence among HIV-infected PWUDs in addiction treatment who report drug- or sex-related HIV risk behaviors.
CONCLUSIONS: This article provides a description of the development and adaptation of the 3H+ intervention, the innovative non-inferiority comparative experimental design for testing the 3H+ to the HHRP+. Furthermore, it provides empirical evidence from a formal cost-effectiveness analysis justifying the cost-effectiveness of the 3H+ intervention when compared to the HHRP+ intervention. If confirmed to be comparable and more cost-effective, as hypothesized, the 3H+ intervention has the potential to be readily and immediately integrated within common clinical settings where large numbers of HIV-infected PWUDs receive clinical services.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiretroviral adherence; Drug users; HIV risk reduction; Intervention adaptation; Non-inferiority prospective trial; Secondary HIV prevention

Year:  2015        PMID: 26253181      PMCID: PMC4744142          DOI: 10.1016/j.cct.2015.08.002

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  45 in total

Review 1.  HIV treatment as prevention among injection drug users.

Authors:  Evan Wood; Michael John Milloy; Julio S G Montaner
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

Review 2.  Neurocognitive impairment and HIV risk factors: a reciprocal relationship.

Authors:  Pria Anand; Sandra A Springer; Michael M Copenhaver; Frederick L Altice
Journal:  AIDS Behav       Date:  2010-12

3.  The ADAPT-ITT model: a novel method of adapting evidence-based HIV Interventions.

Authors:  Gina M Wingood; Ralph J DiClemente
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

4.  A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users.

Authors:  Arthur Margolin; S Kelly Avants; Lara A Warburton; Keith A Hawkins; Julia Shi
Journal:  Health Psychol       Date:  2003-03       Impact factor: 4.267

5.  Behavioral HIV risk reduction among people who inject drugs: meta-analytic evidence of efficacy.

Authors:  Michael M Copenhaver; Blair T Johnson; I-Ching Lee; Jennifer J Harman; Michael P Carey
Journal:  J Subst Abuse Treat       Date:  2006-07-13

6.  Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.

Authors:  Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega
Journal:  Ann Intern Med       Date:  2012-03-05       Impact factor: 25.391

7.  Psychological and social factors associated with histories of risk for human immunodeficiency virus infection among African-American inner-city women.

Authors:  S C Kalichman; L Y Stevenson
Journal:  J Womens Health       Date:  1997-04       Impact factor: 2.681

8.  Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users.

Authors:  Michael M Copenhaver; I-Ching Lee; Arthur Margolin; Robert D Bruce; Frederick L Altice
Journal:  Subst Abus       Date:  2011-01       Impact factor: 3.716

9.  Prevention and treatment produced large decreases in HIV incidence in a model of people who inject drugs.

Authors:  Brandon D L Marshall; Samuel R Friedman; João F G Monteiro; Magdalena Paczkowski; Barbara Tempalski; Enrique R Pouget; Mark N Lurie; Sandro Galea
Journal:  Health Aff (Millwood)       Date:  2014-03       Impact factor: 6.301

10.  Strategies for primary HIV prevention that target behavioral change.

Authors:  Steven A Safren; Gina Wingood; Frederick L Altice
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

View more
  6 in total

1.  Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment.

Authors:  Tania B Huedo-Medina; Roman Shrestha; Michael Copenhaver
Journal:  AIDS Behav       Date:  2016-08

2.  Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART).

Authors:  Roman Shrestha; Michael M Copenhaver
Journal:  Addict Behav       Date:  2018-05-31       Impact factor: 3.913

3.  Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment.

Authors:  Roman Shrestha; Pramila Karki; Tania B Huedo-Medina; Michael Copenhaver
Journal:  J Assoc Nurses AIDS Care       Date:  2016-09-22       Impact factor: 1.354

4.  Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment.

Authors:  Roman Shrestha; Frederick L Altice; Tania B Huedo-Medina; Pramila Karki; Michael Copenhaver
Journal:  AIDS Behav       Date:  2017-05

5.  HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients.

Authors:  Roman Shrestha; Frederick L Altice; Michael M Copenhaver
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

6.  Delivery of long-term-injectable agents for TB by lay carers: pragmatic randomised trial.

Authors:  Danielle B Cohen; Kuzani Mbendera; Hendramoorthy Maheswaran; Mavuto Mukaka; Helen Mangochi; Linna Phiri; Jason Madan; Geraint Davies; Elizabeth Corbett; Bertel Squire
Journal:  Thorax       Date:  2019-11-01       Impact factor: 9.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.